Eden Research (AIM:EDEN) reported revenue of £4.9 million for the 15 months to 31 March, up from £4.3 million in the year to December 2024, as the AIM-listed biopesticide developer widened its operating loss to £2.9 million from £2.2 million.
The company, which develops biopesticide and biocontrol products for sustainable agriculture, changed its accounting reference date during the period, extending the reporting window from a calendar year to 15 months to better align with the Northern Hemisphere growing season.
Cash fell to £1.5 million at period-end from £3.7 million a year earlier, though Eden completed a £10.8 million fundraise in the second quarter of 2026 to fund development of its insecticide and second-generation fungicide candidates.
Regulatory progress featured heavily in the period: flagship fungicide Mevalone secured approval for powdery mildew control on Californian grapes, gained a French label extension covering downy and powdery mildew, and its enhanced variant Novellus+ received its first South American approval in Chile.
Syngenta was appointed exclusive distribution partner for ornamental crops across the EU and UK, while Andermatt Kenya took on exclusive Mevalone distribution in Kenya.
"I remain very confident in the company, its products, technologies, and its commercial prospects and am pleased to report another successful period of progress", said chairman Lykele van der Broek.
The board's full-year expectations remain unchanged, though management flagged that hot, dry conditions in Europe and the US can reduce disease pressure, shortening in-season application and potentially leaving distributors with more unsold stock.
Eden said it continues to negotiate with two lead candidates for its insecticide product, targeting an agreement by the end of 2026.
News Intelligence what this means for the company
Eden Research reported 15% revenue growth to £4.9 million but widened its operating loss to £2.9 million, driven by an extended 15-month reporting period aligned to the growing season. The company secured regulatory approvals across the US, France, and Chile for its flagship Mevalone fungicide and variant Novellus+, and signed distribution partnerships with Syngenta (EU/UK ornamentals) and Andermatt Kenya. However, cash fell sharply to £1.5 million from £3.7 million despite completing a £10.8 million fundraise in Q2 2026, indicating rapid cash burn, and management warned that favourable weather conditions in key markets could suppress near-term demand.
- Syngenta's appointment as exclusive EU/UK ornamental distributor signals commercial validation but creates execution risk: Eden's revenue growth depends on Syngenta's sales effort and inventory management in a market where weather-driven disease pressure is volatile.
- The £10.8 million raise, completed mid-period, was substantially depleted by period-end (£1.5 million cash remaining), implying a burn rate of roughly £2.2 million per quarter; future funding needs are material unless revenue accelerates materially or the company reaches profitability.
Regulatory momentum is real, three new geographic approvals in one period and two distribution partnerships validate the product, but the company remains pre-scale: revenue of £4.9 million over 15 months against an operating loss of £2.9 million shows the commercialisation phase is capital-intensive and weather-dependent. The sharp cash depletion and management's own caveat that benign conditions reduce demand create near-term uncertainty around cash runway and the timing of profitability.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
